Starboard-Driven Perrigo Sees CEO Depart After CFO

Perrigo's CEO John Hendrickson, who was appointed to the post when Joseph Papa left to head Valeant in 2016, is to retire. The company is also looking for a permanent CFO after Judy Brown left in February. The departures follow a board shake-up pushed through by activist investor Starboard Value LP.

Helm — Who will take the helm at Perrigo following Starboard pressure? • Source: Shutterstock

Perrigo Co. PLC is back to searching for a CEO after announcing the retirement of John Hendrickson just 14 months into his tenure. Hendrickson took over as CEO following the departure of Joseph Papa in 2016, but before Starboard Value LP stepped into the frame as an activist investor agitating for change.

Hendrickson's retirement follows the resignation of chief financial officer Judy Brown in February 2017, which was also the month that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

What Incyte Investors Expect From New CEO Bill Meury

27 Jun 2025

• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Executives On The Move: New CEO At Atalanta Therapeutics

27 Jun 2025

Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

26 Jun 2025

• By Kevin Grogan

The biotech had been looking at options to survive since May.

Executives On The Move: Fable Therapeutics Gains CMO From AstraZeneca

20 Jun 2025

Recent moves in the industry include changes at the top at 32 Biosciences, plus new CEOs at Idorsia, Courage Therapeutics and Oncolytics Biotech.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

27 Jun 2025

• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.